Every material Form 8-K Insight Molecular Diagnostics Inc. has filed with the SEC since June 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Insight Molecular Diagnostics (iMDx) entered into Amendment No. 2 to its Chronix merger agreement on September 15, 2026, with equity holder representative David MacKenzie. The amendment sets the earnout for CNI Monitor sales at a 10% royalty that ends on a sale of CNI Monitor rights or patent expiration, replaced by a final 10% of gross sale proceeds on any such sale. The filing gives no dollar amounts, so the financial effect on shareholders cannot be determined from it.
Amendment No. 2 is dated September 15, 2026, between iMDx and David MacKenzie, solely as Equityholder Representative.
Chronix equity holders keep a 10% royalty on CNI Monitor sales until the earlier of a CNI Monitor sale or expiration of related intellectual property.
On a CNI Monitor sale, holders receive a final payment of 10% of gross proceeds, which ends the ongoing royalty.
The filing gives no dollar amounts; the full amendment is filed as Exhibit 2.1.
Insight Molecular Diagnostics reported second-quarter 2026 revenue of $239,000, down from $518,000 a year earlier, and a net loss of $11.3 million, or $0.31 per share, versus $9.7 million, or $0.30 per share, in the prior-year quarter. The company also disclosed that the FDA issued an Additional Information Request on its GraftAssureDx submission, which requires a complete response within 180 days; management calls the request routine.
Q2 2026 revenue was $239,000 versus $518,000 in Q2 2025; gross profit was $157,000.
Q2 2026 net loss was $11.3 million ($0.31 per share) versus $9.7 million ($0.30 per share) in Q2 2025; non-GAAP net loss was $8.3 million ($0.23 per share).
The FDA issued an Additional Information Request on GraftAssureDx, with a complete response due within 180 days; the company expects one more FDA meeting before the fourth quarter of 2026.
Cash, cash equivalents and restricted cash was $18.7 million at June 30, 2026; Q2 free cash outflow was approximately $10 million.
At its June 11, 2026 annual meeting, Insight Molecular Diagnostics shareholders approved an amendment adding 1,750,000 shares to its equity incentive plan, bringing the total authorized to 5,550,000 shares. All four director nominees were re-elected, and the shareholders also ratified CBIZ CPAs P.C. as auditor and approved executive pay on an advisory basis. The filing reports routine annual meeting outcomes and does not describe any change in leadership or finances.
Plan amendment approved: 19,117,865 votes for, 122,829 against, 4,799 abstained
Total shares authorized under the Incentive Plan rises to 5,550,000 from 3,800,000 (1,750,000 added)
Four directors elected to serve until the 2027 annual meeting: Joshua Riggs, Andrew Arno, Andrew J. Last and Louis E. Silverman
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Insight Molecular Diagnostics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →